Fennec Pharms Inc Drug Patent Portfolio

Fennec Pharms Inc owns 1 orange book drug protected by 7 US patents Given below is the list of Fennec Pharms Inc's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11291728 Anhydrous sodium thiosulfate and formulations thereof 01 Jul, 2039
Active
US11510984 Anhydrous sodium thiosulfate and formulations thereof 01 Jul, 2039
Active
US11617793 Anhydrous sodium thiosulfate and formulations thereof 01 Jul, 2039
Active
US11964018 Therapeutic uses for sodium thiosulfate formulations 01 Jul, 2039
Active
US11992530 Therapeutic uses for sodium thiosulfate and formulations 01 Jul, 2039
Active
US11998604 Therapeutic uses for sodium thiosulfate formulations 01 Jul, 2039
Active
US10596190 Method for reducing ototoxicity in pediatric patients receiving platinum-based chemotherapy 05 Jan, 2038
Active


Given below is the list of recent legal activities going on the following drug patents of Fennec Pharms Inc.

Activity Date Patent Number
Patent litigations
Mail Patent eCofC Notification 16 Jul, 2024 US11617793
Email Notification 16 Jul, 2024 US11617793
Patent eCofC Notification 16 Jul, 2024 US11617793
Recordation of Patent eCertificate of Correction 16 Jul, 2024 US11617793
Mail Certificate of Correction Memo 30 May, 2024 US11291728
Certificate of Correction Memo 29 May, 2024 US11291728
Patent Issue Date Used in PTA Calculation 23 Apr, 2024 US11964018
Mail Patent eGrant Notification 23 Apr, 2024 US11964018
Email Notification 23 Apr, 2024 US11964018
Recordation of Patent eGrant 23 Apr, 2024 US11964018
Patent eGrant Notification 23 Apr, 2024 US11964018
Recordation of Patent Grant Mailed 23 Apr, 2024 US11964018
Mail Patent eCofC Notification 09 Apr, 2024 US11510984
Recordation of Patent eCertificate of Correction 09 Apr, 2024 US11510984
Patent eCofC Notification 09 Apr, 2024 US11510984


Fennec Pharms Inc's Drug Patent Litigations

Fennec Pharms Inc's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 29, 2021, against patent number US10596190. The petitioner Hope Medical Enterprises, Inc., challenged the validity of this patent, with Oregon Health & Science University et al. as the respondent. Click below to track the latest information on how companies are challenging Fennec Pharms Inc's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US10596190 October, 2021 Final Written Decision
(18 Apr, 2023)
Oregon Health & Science University et al. Hope Medical Enterprises, Inc.


Fennec Pharms Inc's Family Patents

Fennec Pharms Inc drugs have patent protection in a total of 13 countries. It's US patent count contributes only to 35.3% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click below to unlock the full patent family tree.

Family Patents



Fennec Pharms Inc Drug List

Given below is the complete list of Fennec Pharms Inc's drugs and the patents protecting them.


1. Pedmark

Pedmark is protected by 7 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11291728 Anhydrous sodium thiosulfate and formulations thereof 01 Jul, 2039
(14 years from now)
Active
US11510984 Anhydrous sodium thiosulfate and formulations thereof 01 Jul, 2039
(14 years from now)
Active
US11617793 Anhydrous sodium thiosulfate and formulations thereof 01 Jul, 2039
(14 years from now)
Active
US11964018 Therapeutic uses for sodium thiosulfate formulations 01 Jul, 2039
(14 years from now)
Active
US11992530 Therapeutic uses for sodium thiosulfate and formulations 01 Jul, 2039
(14 years from now)
Active
US11998604 Therapeutic uses for sodium thiosulfate formulations 01 Jul, 2039
(14 years from now)
Active
US10596190 Method for reducing ototoxicity in pediatric patients receiving platinum-based chemotherapy 05 Jan, 2038
(13 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Pedmark's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List